Clinical effects of reported synthetic cannabinoid exposure in patients admitted to the intensive care unit

Abstract

ObjectiveTo characterize the clinical presentation and hospital course of patients with reported synthetic cannabinoid (SC) exposure requiring Intensive Care Unit (ICU) admission. DesignRetrospective case series of patients admitted to medical or cardiac ICU. SettingUrban tertiary care center. ParticipantsAdults ≥18 years old admitted from the emergency department (ED) in 2015. MeasurementsDemographics, Sequential Organ Failure Assessment (SOFA) scores, and clinical parameters documenting the effects and hospital course. Results23 patients met inclusion criteria. Median age was 47 years (interquartile range [IQR], 32–54); 83% male; 78% black. Patients were generally tachycardic (HR > 100), (65%) and hypertensive (SBP > 140), (65%) on admission. The initial chest X-ray and ECG were abnormal in 43% and 68% of patients, respectively. Pulmonary edema and tachycardia were the most common findings. Head CT imaging was abnormal in 5% of patients. Troponin was elevated >1.0 ng/ml in 3 of 19 patients (16%). Other exposures detected on admission were marijuana (30%), alcohol (30%), and benzodiazepines (26%). The median SOFA score was 6 on admission and decreased over the next 3 days. SOFA scores were primarily driven by altered neurologic status and respiratory failure. 91% required mechanical ventilation, 30% had seizures as a part of presentation, 18% required vasopressors, and 5% needed dialysis. Median hospital and ICU lengths of stay were 2.6 (IQR 1.4–3.5) and 1.6 (IQR 0.9–2.5) days, respectively. The median hospital charge was $37,008. All patients survived the index hospitalization. ConclusionsPatients admitted to ICU after SC exposure exhibit significant organ dysfunction, particularly neurologic and respiratory. Prognosis is good with supportive care.